Infliximab (Anti–Tumor Necrosis Factor α Antibody)
نویسندگان
چکیده
منابع مشابه
Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor α monoclonal antibody (Infliximab)
Behçet's disease (BD) is a chronic relapsing multisystem disease characterized by oral ulceration, genital ulceration and ocular lesions. Gastrointestinal involvement is rare, often difficult to treat and associated with a high mortality rate. We treated a 47-year-old Korean man with BD who had a recurrent intestinal ulcer with tumor necrosis factor alpha antibody (infliximab); he initially und...
متن کاملAnti‐inflammatory effects of infliximab in mice are independent of tumour necrosis factor α neutralization
Infliximab (IFX) has been used repeatedly in mouse preclinical models with associated claims that anti-inflammatory effects are due to inhibition of mouse tumour necrosis factor (TNF)-α. However, the mechanism of action in mice remains unclear. In this study, the binding specificity of IFX for mouse TNF-α was investigated ex vivo using enzyme-linked immunosorbent assay (ELISA), flow cytometry a...
متن کاملAnti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis.
Preclinical studies based on in vitro cell systems and in vivo models had established a position for tumour necrosis factor (TNF) á as a pivotal molecule regulating cellular activation and interactions in rheumatoid inflammation by 1992. That neutralisation of TNFá has a profound impact on the biology of inflammation is reflected by the rapid reduction in the concentration of C reactive protein...
متن کاملReduction of burn progression with topical delivery of (antitumor necrosis factor-α)-hyaluronic acid conjugates.
In this study, we explored whether topical application of antibodies targeting tumor necrosis factor-α (TNF-α) or interleukin-6 (IL-6) conjugated to hyaluronic acid (HA) could reduce the extension of necrosis by modulating inflammation locally in a partial-thickness rat burn model. Partial-thickness to deep partial-thickness burn injuries present significant challenges in healing, as these burn...
متن کاملRheumatoid Arthritis: Refractory to Infliximab, a Tumor Necrosis Factor Inhibitor
UNLABELLED Rheumatoid arthritis is one of the commonest autoimmune diseases. It is a chronic, progressive, systemic inflammatory disorder affecting the synovial joints and typically producing symmetrical arthritis. If left untreated, it leads to joint destruction and thus deformity and disability.In the recent years, advances in molecular biology have led to a variety of new treatment approache...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Archives of Dermatology
سال: 2001
ISSN: 0003-987X
DOI: 10.1001/archderm.137.12.1571